Castle Biosciences (CSTL) Total Non-Current Liabilities (2018 - 2026)

Castle Biosciences has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $84.9 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $84.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $84.9 million (changed N/A YoY), and the FY2025 annual result was $106.2 million, up 40.83% from the prior year.
• Total Non-Current Liabilities came in at $84.9 million for Q1 2026 at Castle Biosciences, down from $106.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $106.2 million in Q4 2025 to a low of $36.6 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $53.1 million (2023), against an average of $63.1 million.
• Across the five-year window, Total Non-Current Liabilities soared 151.53% in 2022 and decreased 11.28% in 2023, its largest moves.
• Castle Biosciences' Total Non-Current Liabilities stood at $48.1 million in 2022, then rose by 29.02% to $62.0 million in 2023, then increased by 21.52% to $75.4 million in 2024, then surged by 40.83% to $106.2 million in 2025, then dropped by 20.05% to $84.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $84.9 million (Q1 2026), $106.2 million (Q4 2025), and $94.2 million (Q3 2025), per Business Quant data.